Tenpoint Therapeutics has launched after the conclusion of a $70 million Series A funding round.

The Cambridge-based biotechnology company’s focus is on restoring vision by way of engineering cell-based therapeutics and in vivo reprogramming to address degenerative ocular diseases.

In vivo reprogramming is a therapeutic approach to regenerative medicine with the aim of delivering a cell-based therapy to an organ or tissue in need of functional restoration without the use of a cellular agent.

The funding round was led by F-Prime Capital, Sofinnova Partners and British Patient Capital.

“At Tenpoint, we are focused exclusively on the eye and on harnessing recent advances in regenerative biology to advance our therapies as we work to change the future for people with vision loss by addressing its underlying causes,” said Tenpoint chief executive and managing director Eddy Anglade.

The participation from British Patient Capital marks its ninth investment in the life sciences sector through its Future Fund: Breakthrough -- a £375 million programme where British Patient Capital co-invests with private sector investors in innovative, R&D-intensive UK companies.

“Tenpoint Therapeutics has been built on the pioneering work of its scientific founders who are recognised leaders in ocular therapies,” said British Patient Capital chief executive Catherine Lewis La Torre. “Their vision combined with research excellence provides the best foundation to develop treatments that could be gamechangers for millions of patients worldwide.”

Share Story: